| Schedule of Financial Statement Information |
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
(In thousands) |
|
2026 |
|
|
2025 |
|
Accounts receivable, net: |
|
|
|
|
|
|
Accounts receivable |
|
$ |
81,802 |
|
|
$ |
92,325 |
|
Less: allowance for credit losses |
|
|
(2,166 |
) |
|
|
(2,070 |
) |
|
|
$ |
79,636 |
|
|
$ |
90,255 |
|
Inventories, net: |
|
|
|
|
|
|
Consumable supplies |
|
$ |
11,296 |
|
|
$ |
13,090 |
|
Finished products |
|
|
44,085 |
|
|
|
43,994 |
|
Work in-process |
|
|
1,466 |
|
|
|
726 |
|
Raw materials |
|
|
11,108 |
|
|
|
11,529 |
|
Less: inventory reserve |
|
|
(3,558 |
) |
|
|
(3,516 |
) |
|
|
$ |
64,397 |
|
|
$ |
65,823 |
|
Other current assets and prepaid expenses: |
|
|
|
|
|
|
Escrow receivable |
|
$ |
19,531 |
|
|
$ |
19,411 |
|
Taxes recoverable |
|
|
6,061 |
|
|
|
11,842 |
|
Prepaid expenses |
|
|
10,106 |
|
|
|
9,423 |
|
Prepaid insurance |
|
|
1,599 |
|
|
|
3,276 |
|
Other receivables |
|
|
2,396 |
|
|
|
4,609 |
|
Other |
|
|
9,755 |
|
|
|
8,168 |
|
|
|
$ |
49,448 |
|
|
$ |
56,729 |
|
Intangible assets, net: |
|
|
|
|
|
|
Customer relationships |
|
$ |
186,064 |
|
|
$ |
186,865 |
|
Technologies |
|
|
808,293 |
|
|
|
811,986 |
|
Trade names |
|
|
49,364 |
|
|
|
49,374 |
|
Covenants not to compete |
|
|
11,423 |
|
|
|
11,426 |
|
Licenses |
|
|
6,409 |
|
|
|
6,422 |
|
Product registrations |
|
|
6,709 |
|
|
|
6,885 |
|
Other |
|
|
7,373 |
|
|
|
7,518 |
|
Less: accumulated amortization |
|
|
(579,284 |
) |
|
|
(564,200 |
) |
|
|
$ |
496,351 |
|
|
$ |
516,276 |
|
Accrued expenses: |
|
|
|
|
|
|
Employee benefits and severance |
|
$ |
35,227 |
|
|
$ |
33,777 |
|
Clinical trials |
|
|
4,806 |
|
|
|
4,372 |
|
Commitments and contingencies |
|
|
3,287 |
|
|
|
3,529 |
|
Accrued interest |
|
|
4,082 |
|
|
|
5,439 |
|
Gross to net provision |
|
|
5,793 |
|
|
|
5,897 |
|
Inventory received but not invoiced |
|
|
1,999 |
|
|
|
4,098 |
|
Finance leases short-term |
|
|
1,525 |
|
|
|
1,690 |
|
Professional fees |
|
|
1,881 |
|
|
|
1,455 |
|
Taxes payable |
|
|
4,629 |
|
|
|
3,595 |
|
Royalties |
|
|
1,030 |
|
|
|
1,197 |
|
Commissions |
|
|
948 |
|
|
|
1,047 |
|
Other |
|
|
18,269 |
|
|
|
18,310 |
|
|
|
$ |
83,476 |
|
|
$ |
84,406 |
|
Other long-term liabilities: |
|
|
|
|
|
|
Employee severance |
|
$ |
3,190 |
|
|
$ |
5,540 |
|
Mortgages and other debts payable |
|
|
2,007 |
|
|
|
2,262 |
|
Finance leases long-term |
|
|
3,005 |
|
|
|
3,394 |
|
Other |
|
|
11,380 |
|
|
|
11,603 |
|
|
|
$ |
19,582 |
|
|
$ |
22,799 |
|
|
| Schedule of Goodwill |
The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2026.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2026 |
|
|
|
(In thousands) |
|
Gross
goodwill at
January 1,
2026 |
|
|
Cumulative
impairment
at
January 1 |
|
|
Foreign
exchange
and other |
|
|
Balance at March 31, 2026 |
|
|
|
Pharmaceuticals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURNA |
|
$ |
4,827 |
|
|
$ |
(4,827 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
|
Rayaldee |
|
|
89,510 |
|
|
|
— |
|
|
|
(1,758 |
) |
|
|
87,752 |
|
|
|
FineTech |
|
|
11,698 |
|
|
|
(11,698 |
) |
|
|
— |
|
|
|
— |
|
|
|
ModeX |
|
|
80,260 |
|
|
|
— |
|
|
|
— |
|
|
|
80,260 |
|
|
|
OPKO Biologics |
|
|
139,784 |
|
|
|
— |
|
|
|
— |
|
|
|
139,784 |
|
|
|
OPKO Chile |
|
|
3,553 |
|
|
|
— |
|
|
|
(107 |
) |
|
|
3,446 |
|
|
|
OPKO Health Europe |
|
|
7,740 |
|
|
|
— |
|
|
|
(156 |
) |
|
|
7,584 |
|
|
|
OPKO Mexico |
|
|
100 |
|
|
|
(100 |
) |
|
|
— |
|
|
|
— |
|
|
|
Transition Therapeutics |
|
|
3,421 |
|
|
|
(3,421 |
) |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BioReference |
|
|
163,442 |
|
|
|
— |
|
|
|
— |
|
|
|
163,442 |
|
|
|
OPKO Diagnostics |
|
|
17,977 |
|
|
|
(17,977 |
) |
|
|
— |
|
|
|
— |
|
|
|
|
|
$ |
522,312 |
|
|
$ |
(38,023 |
) |
|
$ |
(2,021 |
) |
|
$ |
482,268 |
|
|
|
|